MedTrace Logo

Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36

NCT00822705 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-01-14

No results posted yet for this study

Summary

Interaction of GLP-1 and PYY3-36 in the inhibition of food intake in healthy subjects

Conditions

  • Anti Obesity Agent

Interventions

DRUG

Placebo tablet

Control arm

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • CHRISTOPH BEGLINGER, MD · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-11-30
Completion
2009-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00822705 on ClinicalTrials.gov